Kaeluen
2021-08-18
Great ariticle, would you like to share it?
4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025<blockquote>4 只高速增长股票预计到 2025 年销售额将增长 1,100%(或更多)</blockquote>
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":831869709,"tweetId":"831869709","gmtCreate":1629300750301,"gmtModify":1631889671175,"author":{"id":3574839944009539,"idStr":"3574839944009539","authorId":3574839944009539,"authorIdStr":"3574839944009539","name":"Kaeluen","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Great ariticle, would you like to share it?</p></body></html>","htmlText":"<html><head></head><body><p>Great ariticle, would you like to share it?</p></body></html>","text":"Great ariticle, would you like to share it?","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/831869709","repostId":1122814365,"repostType":4,"repost":{"id":"1122814365","kind":"news","pubTimestamp":1629292156,"share":"https://www.laohunote.com/m/news/1122814365?lang=zh_CN&edition=full","pubTime":"2021-08-18 21:09","market":"us","language":"en","title":"4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025<blockquote>4 只高速增长股票预计到 2025 年销售额将增长 1,100%(或更多)</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122814365","media":"Motley Fool","summary":"Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade.\n\nKey P","content":"<p> <b>Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade.</b> <b>Key Points</b></p><p><blockquote><b>到本世纪中期,这些快节奏股票的收入应该会飙升 1,100% 至 4,200%。</b><b>要点</b></blockquote></p><p> <ul> <li>Rapid sales growth doesn't always tell you the full story about a company.</li> </ul> For the past 12 years, growth stocks have been all the rage on Wall Street -- and with good reason. Historically low lending rates and abundant access to this cheap capital have fueled hiring, innovation, and even acquisitions among fast-paced companies.</p><p><blockquote><ul><li>快速的销售增长并不总是能告诉你一家公司的全部情况。</li></ul>在过去的12年里,成长型股票在华尔街风靡一时——这是有充分理由的。历史上较低的贷款利率和大量获得这种廉价资本的机会推动了快节奏公司的招聘、创新甚至收购。</blockquote></p><p> But for some growth stocks, the expected uptick in revenue is just getting started. According to consensus estimates from Wall Street, the following four hypergrowth stocks are expected to increase their sales by anywhere from 1,100% to more than 4,200% over the next three to five years.</p><p><blockquote>但对于一些成长型股票来说,预期的收入增长才刚刚开始。根据华尔街的一致估计,以下四只高速增长股票预计在未来三到五年内销售额将增长 1,100% 至 4,200% 以上。</blockquote></p><p> <b>Novavax: Implied sales growth of 1,337% by 2025</b></p><p><blockquote><b>Novavax:到 2025 年隐含销售额增长 1,337%</b></blockquote></p><p> Biotech stocksare always a good bet to see their sales rocket from zero to hero with their first drug approval. Clinical-stage drug developer<b>Novavax</b>(NASDAQ:NVAX)is expected to do even more with the expected emergency-use authorization (EUA) approval of its coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373. Per Wall Street, Novavax could see sales catapult from nearly $476 million in 2020 to roughly $6.84 billion by 2025.</p><p><blockquote>随着第一个药物的批准,生物技术股票的销售额从零飙升到英雄总是一个不错的选择。临床阶段药物开发商<b>诺瓦瓦克斯</b>(纳斯达克股票代码:NVAX)预计将在其冠状病毒疾病 2019 (COVID-19) 疫苗 NVX-CoV2373 获得紧急使用授权 (EUA) 批准后取得更多进展。据华尔街报道,Novavax 的销售额可能会从 2020 年的近 4.76 亿美元跃升至 2025 年的约 68.4 亿美元。</blockquote></p><p> To date, Novavax has run two large-scale clinical trials for its COVID-19 vaccine. In March, phase 3 trial data from the U.K. showed a vaccine efficacy (VE) of 89.7%. Data from the second phase 3 study, conducted in the U.S. and Mexico, was released in June and demonstrated a very similar VE of 90.4%. Theeffectiveness of Novavax's vaccinemakes it very likely that it'll soon be authorized in developed markets like the U.S., U.K., and Europe, and could play a key role in emerging markets, as well. Novavax may also push vaccines with lower perceived efficacy --<b>Johnson & Johnson</b> and<b>AstraZeneca</b> -- to the back of the line.</p><p><blockquote>迄今为止,Novavax 已对其 COVID-19 疫苗进行了两项大规模临床试验。3月份,来自英国的3期试验数据显示疫苗效力(VE)为89.7%。在美国和墨西哥进行的第二项 3 期研究的数据于 6 月发布,结果显示 VE 非常相似,为 90.4%。Novavax疫苗的有效性使得它很可能很快就会在美国、英国和欧洲等发达市场获得授权,并可能在新兴市场发挥关键作用。Novavax 还可能推广感知功效较低的疫苗——<b>强生公司</b>和<b>阿斯利康</b>-- 到队伍后面。</blockquote></p><p> The only real drag for Novavax shareholders has been the company'snumerous delays in filing for EUA. Initially expected to go after EUA in the U.S. in the second quarter, the company now anticipates filing the appropriate paperwork during the fourth quarter. There have also been concerns about the company's timeline to ramp up vaccine production to full capacity.</p><p><blockquote>对Novavax股东来说,唯一真正的拖累是该公司在申请EUA方面的多次延迟。该公司最初预计将于第二季度在美国追逐 EUA,现在预计将于第四季度提交适当的文件。人们还担心该公司将疫苗生产提高到满负荷的时间表。</blockquote></p><p> Nevertheless, these delays of a quarter or two aren't going to hamper Novavax's longer-term prospects, which appear to be buoyed by the development of disease variants. The company's ability to quickly develop a vaccine, as well as its early stage research that combines influenza and COVID-19 into a single booster shot, should keep Novavax on the map for a long time to come.</p><p><blockquote>尽管如此,这一两个季度的延迟不会阻碍 Novavax 的长期前景,疾病变异的发展似乎提振了这一前景。该公司快速开发疫苗的能力,以及将流感和 COVID-19 结合到单一加强注射中的早期研究,应该会让 Novavax 在未来很长一段时间内保持知名度。</blockquote></p><p> <b>Blink Charging: Implied sales growth of 2,352% by 2025</b></p><p><blockquote><b>Blink Charging:到 2025 年隐含销售额增长 2,352%</b></blockquote></p><p> Another growth stocks with (pun intended) supercharged sales growth potential over the next five years is<b>Blink Charging</b>(NASDAQ:BLNK). Blink provides electric-vehicle (EV) charging infrastructure, as well as owns charging station networks.</p><p><blockquote>另一只在未来五年内具有(双关语)超强销售增长潜力的成长型股票是<b>闪烁充电</b>(纳斯达克股票代码:BLNK)Blink 提供电动汽车 (EV) 充电基础设施,并拥有充电站网络。</blockquote></p><p> The logic behind Blink's growth is pretty easy to wrap your hands around. Last year, 1.8% of all new vehicles registered in the U.S. were EVs. But by 2025, an IHS Markit study predicts that 10% of all new vehicle registrations will be EVs. As the electrification of America takes shape, demand for charging infrastructureis only going to tick higher. There should be plenty of room for ancillary EV players like Blink Charging to take advantage of this trend for decades to come.</p><p><blockquote>Blink增长背后的逻辑很容易理解。去年,美国注册的所有新车中有 1.8% 是电动汽车。但IHS Markit的一项研究预测,到2025年,所有新车注册量的10%将是电动汽车。随着美国电气化的形成,对充电基础设施的需求只会越来越高。未来几十年,像 Blink Charging 这样的辅助电动汽车玩家应该有足够的空间来利用这一趋势。</blockquote></p><p> Based on Wall Street's consensus estimate, Blink Charging is expected to grow its sales from a reported $6.2 million in 2020 to $152 million by mid-decade. That's a 2,352% revenue increase, for those of you keeping score at home.</p><p><blockquote>根据华尔街的一致估计,Blink Charging 的销售额预计将从 2020 年的 620 万美元增长到 2020 年中期的 1.52 亿美元。对于那些在家记分的人来说,收入增加了 2,352%。</blockquote></p><p> However, Blink's future is far from certain. Its current market cap places it at a multiple of 9 times estimated sales for 2025, and it's not particularly close to generating a profit. The company alsodoesn't appear to be investing any of its cash into research and development. With no true means to stand out, it's quite possible Blink Charging gets left in the dust by its competition.</p><p><blockquote>然而,Blink的未来还远未确定。其目前的市值是 2025 年预计销售额的 9 倍,而且还没有特别接近盈利。该公司似乎也没有将任何现金投入研发。由于没有真正的脱颖而出的手段,Blink Charging很可能会被竞争对手抛在后面。</blockquote></p><p> <b>Jushi Holdings: Implied sales growth of 1,101% by 2024</b></p><p><blockquote><b>巨石控股:到2024年隐含销售额增长1,101%</b></blockquote></p><p> U.S.marijuana stocks are a fantastic bet to deliver triple-digit aggregate sales growth over the next three to five years as new states legalize pot and already legalized states benefit from organic growth. But you can forget about triple-digit sales growth with multistate operator<b>Jushi Holdings</b>(OTC:JUSHF). According to estimates from <b>FactSet</b>, Jushi's projected push to $969 million in annual revenue by 2024 would mark a 1,101% increase from the $80.7 million in sales generated last year.</p><p><blockquote>随着新的州将大麻合法化,并且已经合法化的州将受益于有机增长,美国大麻库存将在未来三到五年内实现三位数的总销售额增长。但您可以忘记多州运营商的三位数销售增长<b>巨石控股</b>(场外交易:JUSHF)。根据估计<b>事实集</b>巨石预计到 2024 年年收入将达到 9.69 亿美元,比去年的 8070 万美元销售额增长 1,101%。</blockquote></p><p></p><p> Operating in the highly lucrative U.S. market is bound to give Jushi a boost. We've already seen 36 states legalize cannabis in some capacity, 18 of which have passed legislation to allow for the consumption and/or retail sale of adult-use weed. If New Frontier Data's latest report on the U.S. pot industry proves accurate, legal weed sales could grow by an annualized average of 21% through 2025, ultimately hitting north of $41 billion.</p><p><blockquote>在利润丰厚的美国市场开展业务必然会给巨石带来提振。我们已经看到36个州在某种程度上将大麻合法化,其中18个州已经通过立法,允许消费和/或零售成人使用的大麻。如果 New Frontier Data 关于美国大麻行业的最新报告被证明是准确的,那么到 2025 年,合法大麻销售额年均增长 21%,最终达到 410 亿美元以上。</blockquote></p><p> Jushi is a relatively small player in the cannabis space, for the time being. It has 20 operating dispensaries, but will likely end the year closer to 30, inclusive of organic openings and acquisitions. The company's core focus is on a trio of limited-license states: Virginia, Pennsylvania, and Illinois. The former issues licenses based on jurisdiction, whereas the latter two limit the aggregate number of retail and cultivation licenses assigned. By targeting limited-license states, Jushi will be somewhat protected from competitors with deeper pockets.</p><p><blockquote>目前,巨石在大麻领域是一个相对较小的参与者。它有20家正在运营的药房,但今年年底可能会接近30家,包括有机开设和收购。该公司的核心重点是三个有限许可州:弗吉尼亚州、宾夕法尼亚州和伊利诺伊州。前者根据管辖权发放许可证,而后两者限制分配的零售和种植许可证的总数。通过瞄准有限许可州,巨石将在一定程度上受到保护,免受财力雄厚的竞争对手的影响。</blockquote></p><p> Similar to Novavax, Jushi is expected to turn the corner to recurring profitability in 2022. It looks to be one of the biggest bargains in the cannabis industry.</p><p><blockquote>与 Novavax 类似,巨石预计将于 2022 年实现经常性盈利。这看起来是大麻行业最大的便宜货之一。</blockquote></p><p> <b>Riot Blockchain: Implied sales growth of 4,231% by 2023</b></p><p><blockquote><b>Riot Blockchain:到 2023 年隐含销售额增长 4,231%</b></blockquote></p><p> The last hypergrowth stock expected to deliver insane revenue growth in the coming years is cryptocurrency miningcompany<b>Riot Blockchain</b>(NASDAQ:RIOT). After reporting just $12.1 million in full-year sales in 2020, Wall Street is expecting Riot to bring in $524 million in revenue by 2023. That's a greater than 4,200% sales increase in just three years.</p><p><blockquote>预计未来几年收入疯狂增长的最后一只高速增长股票是加密货币挖矿公司<b>暴动区块链</b>(纳斯达克股票代码:RIOT)。2020 年全年销售额仅为 1210 万美元,华尔街预计 Riot 到 2023 年将带来 5.24 亿美元的收入。短短三年内销售额增长了 4,200% 以上。</blockquote></p><p> Cryptocurrency miners are people or companies that use high-powered computers to solve complex mathematical equations to validate groups of transactions known as a block. For doing so, crypto miners are paid a block reward. In Riot's case, its revenue is soaring becauseit's building up its farmto mine <b>Bitcoin</b>(CRYPTO:BTC), the world's largest digital currency by market cap. The Bitcoin block reward equates to 6.25 Bitcoin, which is worth about $287,000, as of August 15.</p><p><blockquote>加密货币矿工是使用高性能计算机解决复杂数学方程以验证称为块的交易组的个人或公司。为此,加密矿工会获得区块奖励。以 Riot 为例,其收入正在飙升,因为它正在将农场建设到矿山<b>比特币</b>(加密货币:BTC),全球市值最大的数字货币。截至 8 月 15 日,比特币区块奖励相当于 6.25 比特币,价值约 287,000 美元。</blockquote></p><p> As of the end of July, Riot Blockchain held approximately 2,687 Bitcoin on its balance sheet (these are tokens the company has mined since inception), with plans to have 25,946 Antminers in operation by early September. The goal for Riot Blockchain is to have its full fleet of miners (81,146 Antminers) in operation by the fourth quarter of 2022.</p><p><blockquote>截至 7 月底,Riot Blockchain 的资产负债表上持有约 2,687 个比特币(这些是该公司自成立以来一直在挖掘的代币),计划到 9 月初有 25,946 个蚂蚁矿机投入运营。Riot Blockchain的目标是到2022年第四季度让其全部矿工车队(81,146名蚂蚁矿工)投入运营。</blockquote></p><p> While the sales growth in Bitcoin mining stocks is undeniable, therisks are hard to overlook, as well. Instead of being reliant on innovation, Riot is entirely dependent on investor sentiment in Bitcoin and the price of the token. We've also witnessed three declines of at least 80% in Bitcoin over the past decade, which could potentially crush Riot Blockchain's operating model.</p><p><blockquote>虽然比特币矿业股的销售增长是不可否认的,但风险也不容忽视。Riot 并不依赖创新,而是完全依赖于比特币的投资者情绪和代币价格。过去十年,我们还目睹了比特币三次至少 80% 的下降,这可能会粉碎 Riot Blockchain 的运营模式。</blockquote></p><p> But the real concern is that there's no barrier to entry in the crypto mining space, and Bitcoin block rewards will halve to 3.125 tokens by 2024. This is a highly competitive space with decreasing rewards.</p><p><blockquote>但真正令人担忧的是,进入加密货币挖矿领域没有障碍,到 2024 年,比特币区块奖励将减半至 3,125 个代币。这是一个竞争激烈的领域,奖励越来越少。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025<blockquote>4 只高速增长股票预计到 2025 年销售额将增长 1,100%(或更多)</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025<blockquote>4 只高速增长股票预计到 2025 年销售额将增长 1,100%(或更多)</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-08-18 21:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p> <b>Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade.</b> <b>Key Points</b></p><p><blockquote><b>到本世纪中期,这些快节奏股票的收入应该会飙升 1,100% 至 4,200%。</b><b>要点</b></blockquote></p><p> <ul> <li>Rapid sales growth doesn't always tell you the full story about a company.</li> </ul> For the past 12 years, growth stocks have been all the rage on Wall Street -- and with good reason. Historically low lending rates and abundant access to this cheap capital have fueled hiring, innovation, and even acquisitions among fast-paced companies.</p><p><blockquote><ul><li>快速的销售增长并不总是能告诉你一家公司的全部情况。</li></ul>在过去的12年里,成长型股票在华尔街风靡一时——这是有充分理由的。历史上较低的贷款利率和大量获得这种廉价资本的机会推动了快节奏公司的招聘、创新甚至收购。</blockquote></p><p> But for some growth stocks, the expected uptick in revenue is just getting started. According to consensus estimates from Wall Street, the following four hypergrowth stocks are expected to increase their sales by anywhere from 1,100% to more than 4,200% over the next three to five years.</p><p><blockquote>但对于一些成长型股票来说,预期的收入增长才刚刚开始。根据华尔街的一致估计,以下四只高速增长股票预计在未来三到五年内销售额将增长 1,100% 至 4,200% 以上。</blockquote></p><p> <b>Novavax: Implied sales growth of 1,337% by 2025</b></p><p><blockquote><b>Novavax:到 2025 年隐含销售额增长 1,337%</b></blockquote></p><p> Biotech stocksare always a good bet to see their sales rocket from zero to hero with their first drug approval. Clinical-stage drug developer<b>Novavax</b>(NASDAQ:NVAX)is expected to do even more with the expected emergency-use authorization (EUA) approval of its coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373. Per Wall Street, Novavax could see sales catapult from nearly $476 million in 2020 to roughly $6.84 billion by 2025.</p><p><blockquote>随着第一个药物的批准,生物技术股票的销售额从零飙升到英雄总是一个不错的选择。临床阶段药物开发商<b>诺瓦瓦克斯</b>(纳斯达克股票代码:NVAX)预计将在其冠状病毒疾病 2019 (COVID-19) 疫苗 NVX-CoV2373 获得紧急使用授权 (EUA) 批准后取得更多进展。据华尔街报道,Novavax 的销售额可能会从 2020 年的近 4.76 亿美元跃升至 2025 年的约 68.4 亿美元。</blockquote></p><p> To date, Novavax has run two large-scale clinical trials for its COVID-19 vaccine. In March, phase 3 trial data from the U.K. showed a vaccine efficacy (VE) of 89.7%. Data from the second phase 3 study, conducted in the U.S. and Mexico, was released in June and demonstrated a very similar VE of 90.4%. Theeffectiveness of Novavax's vaccinemakes it very likely that it'll soon be authorized in developed markets like the U.S., U.K., and Europe, and could play a key role in emerging markets, as well. Novavax may also push vaccines with lower perceived efficacy --<b>Johnson & Johnson</b> and<b>AstraZeneca</b> -- to the back of the line.</p><p><blockquote>迄今为止,Novavax 已对其 COVID-19 疫苗进行了两项大规模临床试验。3月份,来自英国的3期试验数据显示疫苗效力(VE)为89.7%。在美国和墨西哥进行的第二项 3 期研究的数据于 6 月发布,结果显示 VE 非常相似,为 90.4%。Novavax疫苗的有效性使得它很可能很快就会在美国、英国和欧洲等发达市场获得授权,并可能在新兴市场发挥关键作用。Novavax 还可能推广感知功效较低的疫苗——<b>强生公司</b>和<b>阿斯利康</b>-- 到队伍后面。</blockquote></p><p> The only real drag for Novavax shareholders has been the company'snumerous delays in filing for EUA. Initially expected to go after EUA in the U.S. in the second quarter, the company now anticipates filing the appropriate paperwork during the fourth quarter. There have also been concerns about the company's timeline to ramp up vaccine production to full capacity.</p><p><blockquote>对Novavax股东来说,唯一真正的拖累是该公司在申请EUA方面的多次延迟。该公司最初预计将于第二季度在美国追逐 EUA,现在预计将于第四季度提交适当的文件。人们还担心该公司将疫苗生产提高到满负荷的时间表。</blockquote></p><p> Nevertheless, these delays of a quarter or two aren't going to hamper Novavax's longer-term prospects, which appear to be buoyed by the development of disease variants. The company's ability to quickly develop a vaccine, as well as its early stage research that combines influenza and COVID-19 into a single booster shot, should keep Novavax on the map for a long time to come.</p><p><blockquote>尽管如此,这一两个季度的延迟不会阻碍 Novavax 的长期前景,疾病变异的发展似乎提振了这一前景。该公司快速开发疫苗的能力,以及将流感和 COVID-19 结合到单一加强注射中的早期研究,应该会让 Novavax 在未来很长一段时间内保持知名度。</blockquote></p><p> <b>Blink Charging: Implied sales growth of 2,352% by 2025</b></p><p><blockquote><b>Blink Charging:到 2025 年隐含销售额增长 2,352%</b></blockquote></p><p> Another growth stocks with (pun intended) supercharged sales growth potential over the next five years is<b>Blink Charging</b>(NASDAQ:BLNK). Blink provides electric-vehicle (EV) charging infrastructure, as well as owns charging station networks.</p><p><blockquote>另一只在未来五年内具有(双关语)超强销售增长潜力的成长型股票是<b>闪烁充电</b>(纳斯达克股票代码:BLNK)Blink 提供电动汽车 (EV) 充电基础设施,并拥有充电站网络。</blockquote></p><p> The logic behind Blink's growth is pretty easy to wrap your hands around. Last year, 1.8% of all new vehicles registered in the U.S. were EVs. But by 2025, an IHS Markit study predicts that 10% of all new vehicle registrations will be EVs. As the electrification of America takes shape, demand for charging infrastructureis only going to tick higher. There should be plenty of room for ancillary EV players like Blink Charging to take advantage of this trend for decades to come.</p><p><blockquote>Blink增长背后的逻辑很容易理解。去年,美国注册的所有新车中有 1.8% 是电动汽车。但IHS Markit的一项研究预测,到2025年,所有新车注册量的10%将是电动汽车。随着美国电气化的形成,对充电基础设施的需求只会越来越高。未来几十年,像 Blink Charging 这样的辅助电动汽车玩家应该有足够的空间来利用这一趋势。</blockquote></p><p> Based on Wall Street's consensus estimate, Blink Charging is expected to grow its sales from a reported $6.2 million in 2020 to $152 million by mid-decade. That's a 2,352% revenue increase, for those of you keeping score at home.</p><p><blockquote>根据华尔街的一致估计,Blink Charging 的销售额预计将从 2020 年的 620 万美元增长到 2020 年中期的 1.52 亿美元。对于那些在家记分的人来说,收入增加了 2,352%。</blockquote></p><p> However, Blink's future is far from certain. Its current market cap places it at a multiple of 9 times estimated sales for 2025, and it's not particularly close to generating a profit. The company alsodoesn't appear to be investing any of its cash into research and development. With no true means to stand out, it's quite possible Blink Charging gets left in the dust by its competition.</p><p><blockquote>然而,Blink的未来还远未确定。其目前的市值是 2025 年预计销售额的 9 倍,而且还没有特别接近盈利。该公司似乎也没有将任何现金投入研发。由于没有真正的脱颖而出的手段,Blink Charging很可能会被竞争对手抛在后面。</blockquote></p><p> <b>Jushi Holdings: Implied sales growth of 1,101% by 2024</b></p><p><blockquote><b>巨石控股:到2024年隐含销售额增长1,101%</b></blockquote></p><p> U.S.marijuana stocks are a fantastic bet to deliver triple-digit aggregate sales growth over the next three to five years as new states legalize pot and already legalized states benefit from organic growth. But you can forget about triple-digit sales growth with multistate operator<b>Jushi Holdings</b>(OTC:JUSHF). According to estimates from <b>FactSet</b>, Jushi's projected push to $969 million in annual revenue by 2024 would mark a 1,101% increase from the $80.7 million in sales generated last year.</p><p><blockquote>随着新的州将大麻合法化,并且已经合法化的州将受益于有机增长,美国大麻库存将在未来三到五年内实现三位数的总销售额增长。但您可以忘记多州运营商的三位数销售增长<b>巨石控股</b>(场外交易:JUSHF)。根据估计<b>事实集</b>巨石预计到 2024 年年收入将达到 9.69 亿美元,比去年的 8070 万美元销售额增长 1,101%。</blockquote></p><p></p><p> Operating in the highly lucrative U.S. market is bound to give Jushi a boost. We've already seen 36 states legalize cannabis in some capacity, 18 of which have passed legislation to allow for the consumption and/or retail sale of adult-use weed. If New Frontier Data's latest report on the U.S. pot industry proves accurate, legal weed sales could grow by an annualized average of 21% through 2025, ultimately hitting north of $41 billion.</p><p><blockquote>在利润丰厚的美国市场开展业务必然会给巨石带来提振。我们已经看到36个州在某种程度上将大麻合法化,其中18个州已经通过立法,允许消费和/或零售成人使用的大麻。如果 New Frontier Data 关于美国大麻行业的最新报告被证明是准确的,那么到 2025 年,合法大麻销售额年均增长 21%,最终达到 410 亿美元以上。</blockquote></p><p> Jushi is a relatively small player in the cannabis space, for the time being. It has 20 operating dispensaries, but will likely end the year closer to 30, inclusive of organic openings and acquisitions. The company's core focus is on a trio of limited-license states: Virginia, Pennsylvania, and Illinois. The former issues licenses based on jurisdiction, whereas the latter two limit the aggregate number of retail and cultivation licenses assigned. By targeting limited-license states, Jushi will be somewhat protected from competitors with deeper pockets.</p><p><blockquote>目前,巨石在大麻领域是一个相对较小的参与者。它有20家正在运营的药房,但今年年底可能会接近30家,包括有机开设和收购。该公司的核心重点是三个有限许可州:弗吉尼亚州、宾夕法尼亚州和伊利诺伊州。前者根据管辖权发放许可证,而后两者限制分配的零售和种植许可证的总数。通过瞄准有限许可州,巨石将在一定程度上受到保护,免受财力雄厚的竞争对手的影响。</blockquote></p><p> Similar to Novavax, Jushi is expected to turn the corner to recurring profitability in 2022. It looks to be one of the biggest bargains in the cannabis industry.</p><p><blockquote>与 Novavax 类似,巨石预计将于 2022 年实现经常性盈利。这看起来是大麻行业最大的便宜货之一。</blockquote></p><p> <b>Riot Blockchain: Implied sales growth of 4,231% by 2023</b></p><p><blockquote><b>Riot Blockchain:到 2023 年隐含销售额增长 4,231%</b></blockquote></p><p> The last hypergrowth stock expected to deliver insane revenue growth in the coming years is cryptocurrency miningcompany<b>Riot Blockchain</b>(NASDAQ:RIOT). After reporting just $12.1 million in full-year sales in 2020, Wall Street is expecting Riot to bring in $524 million in revenue by 2023. That's a greater than 4,200% sales increase in just three years.</p><p><blockquote>预计未来几年收入疯狂增长的最后一只高速增长股票是加密货币挖矿公司<b>暴动区块链</b>(纳斯达克股票代码:RIOT)。2020 年全年销售额仅为 1210 万美元,华尔街预计 Riot 到 2023 年将带来 5.24 亿美元的收入。短短三年内销售额增长了 4,200% 以上。</blockquote></p><p> Cryptocurrency miners are people or companies that use high-powered computers to solve complex mathematical equations to validate groups of transactions known as a block. For doing so, crypto miners are paid a block reward. In Riot's case, its revenue is soaring becauseit's building up its farmto mine <b>Bitcoin</b>(CRYPTO:BTC), the world's largest digital currency by market cap. The Bitcoin block reward equates to 6.25 Bitcoin, which is worth about $287,000, as of August 15.</p><p><blockquote>加密货币矿工是使用高性能计算机解决复杂数学方程以验证称为块的交易组的个人或公司。为此,加密矿工会获得区块奖励。以 Riot 为例,其收入正在飙升,因为它正在将农场建设到矿山<b>比特币</b>(加密货币:BTC),全球市值最大的数字货币。截至 8 月 15 日,比特币区块奖励相当于 6.25 比特币,价值约 287,000 美元。</blockquote></p><p> As of the end of July, Riot Blockchain held approximately 2,687 Bitcoin on its balance sheet (these are tokens the company has mined since inception), with plans to have 25,946 Antminers in operation by early September. The goal for Riot Blockchain is to have its full fleet of miners (81,146 Antminers) in operation by the fourth quarter of 2022.</p><p><blockquote>截至 7 月底,Riot Blockchain 的资产负债表上持有约 2,687 个比特币(这些是该公司自成立以来一直在挖掘的代币),计划到 9 月初有 25,946 个蚂蚁矿机投入运营。Riot Blockchain的目标是到2022年第四季度让其全部矿工车队(81,146名蚂蚁矿工)投入运营。</blockquote></p><p> While the sales growth in Bitcoin mining stocks is undeniable, therisks are hard to overlook, as well. Instead of being reliant on innovation, Riot is entirely dependent on investor sentiment in Bitcoin and the price of the token. We've also witnessed three declines of at least 80% in Bitcoin over the past decade, which could potentially crush Riot Blockchain's operating model.</p><p><blockquote>虽然比特币矿业股的销售增长是不可否认的,但风险也不容忽视。Riot 并不依赖创新,而是完全依赖于比特币的投资者情绪和代币价格。过去十年,我们还目睹了比特币三次至少 80% 的下降,这可能会粉碎 Riot Blockchain 的运营模式。</blockquote></p><p> But the real concern is that there's no barrier to entry in the crypto mining space, and Bitcoin block rewards will halve to 3.125 tokens by 2024. This is a highly competitive space with decreasing rewards.</p><p><blockquote>但真正令人担忧的是,进入加密货币挖矿领域没有障碍,到 2024 年,比特币区块奖励将减半至 3,125 个代币。这是一个竞争激烈的领域,奖励越来越少。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.fool.com/investing/2021/08/18/4-hypergrowth-stocks-increase-sales-1100-by-2025/\">Motley Fool</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLNK":"Blink Charging","RIOT":"Riot Platforms","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/08/18/4-hypergrowth-stocks-increase-sales-1100-by-2025/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122814365","content_text":"Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade.\n\nKey Points\n\nRapid sales growth doesn't always tell you the full story about a company.\n\nFor the past 12 years, growth stocks have been all the rage on Wall Street -- and with good reason. Historically low lending rates and abundant access to this cheap capital have fueled hiring, innovation, and even acquisitions among fast-paced companies.\nBut for some growth stocks, the expected uptick in revenue is just getting started. According to consensus estimates from Wall Street, the following four hypergrowth stocks are expected to increase their sales by anywhere from 1,100% to more than 4,200% over the next three to five years.\nNovavax: Implied sales growth of 1,337% by 2025\nBiotech stocksare always a good bet to see their sales rocket from zero to hero with their first drug approval. Clinical-stage drug developerNovavax(NASDAQ:NVAX)is expected to do even more with the expected emergency-use authorization (EUA) approval of its coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373. Per Wall Street, Novavax could see sales catapult from nearly $476 million in 2020 to roughly $6.84 billion by 2025.\nTo date, Novavax has run two large-scale clinical trials for its COVID-19 vaccine. In March, phase 3 trial data from the U.K. showed a vaccine efficacy (VE) of 89.7%. Data from the second phase 3 study, conducted in the U.S. and Mexico, was released in June and demonstrated a very similar VE of 90.4%. Theeffectiveness of Novavax's vaccinemakes it very likely that it'll soon be authorized in developed markets like the U.S., U.K., and Europe, and could play a key role in emerging markets, as well. Novavax may also push vaccines with lower perceived efficacy --Johnson & Johnson andAstraZeneca -- to the back of the line.\nThe only real drag for Novavax shareholders has been the company'snumerous delays in filing for EUA. Initially expected to go after EUA in the U.S. in the second quarter, the company now anticipates filing the appropriate paperwork during the fourth quarter. There have also been concerns about the company's timeline to ramp up vaccine production to full capacity.\nNevertheless, these delays of a quarter or two aren't going to hamper Novavax's longer-term prospects, which appear to be buoyed by the development of disease variants. The company's ability to quickly develop a vaccine, as well as its early stage research that combines influenza and COVID-19 into a single booster shot, should keep Novavax on the map for a long time to come.\nBlink Charging: Implied sales growth of 2,352% by 2025\nAnother growth stocks with (pun intended) supercharged sales growth potential over the next five years isBlink Charging(NASDAQ:BLNK). Blink provides electric-vehicle (EV) charging infrastructure, as well as owns charging station networks.\nThe logic behind Blink's growth is pretty easy to wrap your hands around. Last year, 1.8% of all new vehicles registered in the U.S. were EVs. But by 2025, an IHS Markit study predicts that 10% of all new vehicle registrations will be EVs. As the electrification of America takes shape, demand for charging infrastructureis only going to tick higher. There should be plenty of room for ancillary EV players like Blink Charging to take advantage of this trend for decades to come.\nBased on Wall Street's consensus estimate, Blink Charging is expected to grow its sales from a reported $6.2 million in 2020 to $152 million by mid-decade. That's a 2,352% revenue increase, for those of you keeping score at home.\nHowever, Blink's future is far from certain. Its current market cap places it at a multiple of 9 times estimated sales for 2025, and it's not particularly close to generating a profit. The company alsodoesn't appear to be investing any of its cash into research and development. With no true means to stand out, it's quite possible Blink Charging gets left in the dust by its competition.\nJushi Holdings: Implied sales growth of 1,101% by 2024\nU.S.marijuana stocks are a fantastic bet to deliver triple-digit aggregate sales growth over the next three to five years as new states legalize pot and already legalized states benefit from organic growth. But you can forget about triple-digit sales growth with multistate operatorJushi Holdings(OTC:JUSHF). According to estimates from FactSet, Jushi's projected push to $969 million in annual revenue by 2024 would mark a 1,101% increase from the $80.7 million in sales generated last year.\nOperating in the highly lucrative U.S. market is bound to give Jushi a boost. We've already seen 36 states legalize cannabis in some capacity, 18 of which have passed legislation to allow for the consumption and/or retail sale of adult-use weed. If New Frontier Data's latest report on the U.S. pot industry proves accurate, legal weed sales could grow by an annualized average of 21% through 2025, ultimately hitting north of $41 billion.\nJushi is a relatively small player in the cannabis space, for the time being. It has 20 operating dispensaries, but will likely end the year closer to 30, inclusive of organic openings and acquisitions. The company's core focus is on a trio of limited-license states: Virginia, Pennsylvania, and Illinois. The former issues licenses based on jurisdiction, whereas the latter two limit the aggregate number of retail and cultivation licenses assigned. By targeting limited-license states, Jushi will be somewhat protected from competitors with deeper pockets.\nSimilar to Novavax, Jushi is expected to turn the corner to recurring profitability in 2022. It looks to be one of the biggest bargains in the cannabis industry.\nRiot Blockchain: Implied sales growth of 4,231% by 2023\nThe last hypergrowth stock expected to deliver insane revenue growth in the coming years is cryptocurrency miningcompanyRiot Blockchain(NASDAQ:RIOT). After reporting just $12.1 million in full-year sales in 2020, Wall Street is expecting Riot to bring in $524 million in revenue by 2023. That's a greater than 4,200% sales increase in just three years.\nCryptocurrency miners are people or companies that use high-powered computers to solve complex mathematical equations to validate groups of transactions known as a block. For doing so, crypto miners are paid a block reward. In Riot's case, its revenue is soaring becauseit's building up its farmto mine Bitcoin(CRYPTO:BTC), the world's largest digital currency by market cap. The Bitcoin block reward equates to 6.25 Bitcoin, which is worth about $287,000, as of August 15.\nAs of the end of July, Riot Blockchain held approximately 2,687 Bitcoin on its balance sheet (these are tokens the company has mined since inception), with plans to have 25,946 Antminers in operation by early September. The goal for Riot Blockchain is to have its full fleet of miners (81,146 Antminers) in operation by the fourth quarter of 2022.\nWhile the sales growth in Bitcoin mining stocks is undeniable, therisks are hard to overlook, as well. Instead of being reliant on innovation, Riot is entirely dependent on investor sentiment in Bitcoin and the price of the token. We've also witnessed three declines of at least 80% in Bitcoin over the past decade, which could potentially crush Riot Blockchain's operating model.\nBut the real concern is that there's no barrier to entry in the crypto mining space, and Bitcoin block rewards will halve to 3.125 tokens by 2024. This is a highly competitive space with decreasing rewards.","news_type":1,"symbols_score_info":{"NVAX":0.9,"BLNKW":0.9,"RIOT":0.9,"BLNK":0.9}},"isVote":1,"tweetType":1,"viewCount":444,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":36,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/831869709"}
精彩评论